Roche’s Tecentriq scoops up a big win in small cell lung cancer, grabbing the lead in frontline cases
Roche’s Genentech has scored a landmark success in treating small cell lung cancer, reporting that its PD-L1 checkpoint Tecentriq plus chemo helped patients live longer when they received the combo as a frontline therapy. And the score on IMpower133 should put it in the lead in that sector — for now.
Falling on the heels of some setbacks, Genentech execs are reporting that their combination approach offered statistically significant results for both overall survival as well as progression-free survival. The beat over the control arm was also identified at an interim stage, allowing Roche to accelerate plans to get this into the hands of regulators.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.